Pictet Asset Management’s Beam Therapeutics BEAM Stock Holding History

Pictet Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.54M	Sell	297,504 -28,150	-9%	-$781K	0.01%	744
2025 Q4	$9.06M	Sell	325,654 -11,860	-4%	-$303K	0.01%	691
2025 Q3	$8.08M	Buy	337,514 +17,834	+6%	+$355K	0.01%	718
2025 Q2	$5.37M	Buy	319,680 +144,836	+83%	+$2.52M	0.01%	774
2025 Q1	$3.85M	Buy	174,844 +166,466	+1,987%	+$4.36M	﹤0.01%	830
2024 Q4	$208K	Hold	8,378	–	–	﹤0.01%	1843
2024 Q3	$205K	Sell	8,378 -1,278	-13%	-$33K	﹤0.01%	1802
2024 Q2	$226K	Sell	9,656 -292,364	-97%	-$7.18M	﹤0.01%	1697
2024 Q1	$9.98M	Sell	302,020 -50,789	-14%	-$1.58M	0.01%	643
2023 Q4	$9.6M	Sell	352,809 -339,261	-49%	-$8.43M	0.01%	649
2023 Q3	$16.6M	Buy	+692,070	New	+$18.6M	0.02%	504

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Pictet Asset Management's BEAM Position: Q1 2026 in Review

Pictet Asset Management reduced its Beam Therapeutics (BEAM) stake by 8.6% in Q1 2026, selling an estimated $781K and leaving 297,504 shares worth $6.54M. The position accounts for 0.01% of the portfolio, ranked #744.

Pictet Asset Management first reported a position in BEAM in Q3 2023 and has held it in 11 quarters since. The position peaked at $16.6M in Q3 2023. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

Pictet Asset Management held 297,504 shares of Beam Therapeutics worth $6.54M as of Q1 2026.
Pictet Asset Management sold 28,150 Beam Therapeutics shares in Q1 2026, an estimated $781K.
Beam Therapeutics made up 0.01% of Pictet Asset Management's portfolio in Q1 2026, its #744 holding.
Pictet Asset Management first reported a position in Beam Therapeutics in Q3 2023 and has held it in 11 quarters since.
Pictet Asset Management's Beam Therapeutics position peaked at $16.6M in Q3 2023.
251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.